A detailed history of Mariner, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Mariner, LLC holds 13,888 shares of BEAM stock, worth $422,611. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,888
Previous 12,655 9.74%
Holding current value
$422,611
Previous $310,000 10.97%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$21.55 - $30.35 $26,571 - $37,421
1,233 Added 9.74%
13,888 $344,000
Q3 2024

Nov 13, 2024

BUY
$22.57 - $33.14 $73,713 - $108,235
3,266 Added 34.79%
12,655 $310,000
Q2 2024

Aug 13, 2024

BUY
$21.22 - $32.66 $26,185 - $40,302
1,234 Added 15.13%
9,389 $219,000
Q1 2024

May 15, 2024

BUY
$23.46 - $45.07 $12,410 - $23,842
529 Added 6.94%
8,155 $269,000
Q4 2023

Feb 14, 2024

BUY
$17.69 - $30.76 $134,903 - $234,575
7,626 New
7,626 $207,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $2.14B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.